The agency that recommends what drugs should be approved in Europe has thrown its support behind five new ones, including a gene therapy for hemophilia, a combination treatment for liver cancer and a medicine for a rare disorder known as Pompe disease.
While the European Commission still needs to authorize these treatments, the nods from the European Medicines Agency and its drug review committee put them a step closer to market.
